EUCTR2014-001203-50-SE进行中（未招募）1 期
An evaluator-blinded multi-center study of combined treatment with Azzalure, Restylane/Emervel filler and Restylane skinbooster as compared tosingle treatment with either Azzalure alone or Restylane/Emervel filler alone - 05DF1211 (Study 1)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Q-med AB
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subjects aged 35 to 50 years old
- •2. Subjects with the intention to undergo facial aesthetic treatment and who are likely to benefit from a combination of injection treatments and the benefit can be shown by improvements in their global facial aesthetic appearance and satisfaction
- •3. Subjects with nasolabial folds assessed as mild or moderate
- •4. Subjects with glabellar lines assessed as moderate or severe, when the severity of the lines has an important psychological impact on the subject
- •5. Subjects with signed informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Current facial conditions
- •1. Subjects requiring treatment of forehead lines or crow´s feet
- •2. Obvious facial sagging (major loss of facial fat/volume)
- •3. Signs or symptoms of eyelid ptosis or signs of compensatory frontalis muscle activity
- •4. Heavily scarred or sun-damaged facial skin
- •5. Active skin disease, inflammation or related conditions, such as infection, psoriasis and herpes zoster near or on the areas to be treated
- •6. Cancerous or pre-cancerous lesions in the areas to be treated
- •Previous facial/dermatological procedures
- •7. Facial tissue augmenting therapy or revitalization treatment with hyaluronic acid (HA) or collagen, or botulinum toxin treatment during the last 12 months
- •8. Procedures or treatments inducing an active dermal response such as laser, Intense Pulsed Light, chemical peeling, microdermabrasion, retinoids within the last 6 months
- •9. Any aesthetic surgery of the face
- •10. Permanent implant or aesthetic treatment with non-HA or non-collagen products in the face
- •Medical history and current health/medications
- •11. History of severe keloids and/or hypertrophic scars
- •12. Neuromuscular junctional disorders (e.g. myasthenia gravis, Eaton Lambert syndrome or amyotrophic lateral sclerosis) or history of dysphagia and aspiration
- •13. Known hypersensitivity to hyaluronic acid, botulinum toxin, lidocaine hydrochloride or other amide-type anesthetics
- •14. History of autoimmune diseases
- •15. Any medical condition that in the opinion of the investigator would make the subject unsuitable for inclusion (e.g. a chronic, relapsing or hereditary disease that may affect the general condition or may require frequent medical treatment)
- •16. Concomitant anticoagulant therapy and therapy with inhibitors of platelet aggregation (e.g. aspirin or other nonsteroidal anti-inflammatory drugs [NSAIDs]), Omega-3 or vitamin E within 10 days before study treatment, or a history of bleeding disorders
- •17. Immunosuppressive therapy, chemotherapy, or systemic corticosteroids within the last 3 months prior to baseline visit.
- •18. Female subjects who are pregnant or plan to become pregnant within the study timeframe, or who are nursing.
- •19. Participation in any other clinical study within 30 days prior to inclusion
- •20. Other condition preventing the subject to entering the study in the Investigator’s opinion e.g. subjects not likely to avoid other facial procedures that might interfere with the outcome of the study, subjects anticipated to be unreliable or incapable of understanding the study assessment or unrealistic expectations of treatment result
- •21. Study site staff or close relative to study site staff (e.g. parents, children, siblings or spouse) and employees at the sponsor company or close relatives to employees at the sponsor company
研究者
相似试验
进行中（未招募）
1 期
An study to compare combined treatment with Azzalure/Dysport, Restylane/Emervel filler and Restylane skinbooster with single treatment with either Azzalure/Dysport alone or Restylane/Emervel filler aloneSubjects with the intention to undergo facial aesthetic treatment and who are likely to benefit from a combination of injection treatmentsEUCTR2014-001202-17-SEQ-med AB60
未知
不适用
A prospective multicenter study of combination of peripheral arterial disease in spine surgery and relation with perioperative complications.JPRN-UMIN000002115agoya university Graduate School of Medicine300
进行中（未招募）
不适用
A Multi-center, Double-blind Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects with Moderate to Severe Crohn's Disease - NDModerate to severe Crohn's diseaseMedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's diseaseEUCTR2006-004814-41-ITAbbott GmbH & Co. KG184
进行中（未招募）
不适用
A multicenter, randomized, rater-blind study to compare the efficacy and safety of natalizumab (300 mg IV every four weeks) with Interferon beta-1a (44 mcg SC three times a week) in subjects with relapsing multiple sclerosis previously treated with Interferon beta-1a (22 or 44 mcg SC three times a week).Male and female subjects with relapsing multiple sclerosis previously treated with interferon beta-1a (22 mcg or 44 mcg, SC three times a week).EUCTR2004-004130-14-ATBiogen Idec GmbH1,050
进行中（未招募）
不适用
A study of RoActemra/Actemra (tocilizumab) in combination with methotrexate in patients with rheumatoid arthritis with inadequate response to prior treatment with methotrexate and low disease activity with the combination de RoActemra/Actemra y methotrexate.MedDRA version: 14.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid arthritisEUCTR2011-001626-15-ESRoche Farma, S.A.